Fusion molecules of CTLA4 and IL-15
US12297247B2 · kind B2 · utility
0Cited by
0References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 19, 2023 |
| Grant date | May 13, 2025 |
| Priority date | — |
| Expiry date | Jul 19, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/32
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Soluble fusion protein complexes, including domains from IL-15, IL-15 receptor, and αCTLA4 antibody for preventing, reducing the occurrence of, and/or treating cancer or an autoimmune disease or disorder in a subject are provided herein. The methods provided herein include administering to a subject a pharmaceutical composition of a soluble fusion protein complex.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.